Nomura lifts Gland Pharma stock rating to neutral, trims target

Published 20/01/2025, 12:22
Nomura lifts Gland Pharma stock rating to neutral, trims target

On Monday, Nomura/Instinet shifted its stance on Gland Pharma (NS:GLAD) Ltd (GLAND:IN), raising the stock rating from Reduce to Neutral. The firm also adjusted the price target slightly to INR 1,790.00, down from the previous INR 1,800.00. Nomura analysts cited a mix of factors that could influence the pharmaceutical company's future performance, including an anticipated improvement in US exports.

The analysts noted that Gland Pharma's US exports were subdued in the third quarter of fiscal year 2025 due to reduced supplies of Enoxaparin. However, the management expects this to pick up in the fourth quarter of the fiscal year. Nomura believes this could lead to a better product mix and potentially enhance the company's year-over-year gross margin.

Further insights from the analysts suggest that Cenexi, a recent acquisition by Gland Pharma, is projected to show quarter-over-quarter improvement in sales and EBITDA margins, nearing EBITDA breakeven in the fourth quarter of fiscal year 2025. The earnings model was restated by Nomura to reflect the company's performance in the first nine months of fiscal year 2025 and recent foreign exchange movements.

As a result of these revisions, Nomura has reduced its earnings per share (EPS) forecasts for Gland Pharma for fiscal years 2025, 2026, and 2027 by 4.7%, 4.6%, and 4.0%, respectively. The report includes revenue projections for Cenexi, with estimates of EUR 171 million, EUR 210 million, and EUR 240 million for the fiscal years 2025, 2026, and 2027. EBITDA margin forecasts for Cenexi are set at 3.9% for fiscal year 2026 and 11.4% for fiscal year 2027.

Excluding Cenexi, Nomura's EBITDA margin estimates for Gland Pharma are 33.1%, 34.8%, and 35.3% for fiscal years 2025, 2026, and 2027, respectively. The analysts also mentioned that currency depreciation and volume increases from a low base in fiscal year 2025, along with potential fill-finish opportunities for GLP-1 drugs, could support EBITDA margin expansion over the next two fiscal years.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.